Wall Street Zen upgraded shares of Afya (NASDAQ:AFYA – Free Report) from a hold rating to a buy rating in a research note published on Sunday,Wall Street Zen reports.
AFYA has been the topic of a number of other reports. Zacks Research downgraded shares of Afya from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. Citigroup raised shares of Afya from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $16.00 to $12.00 in a research report on Tuesday, November 3rd. Weiss Ratings cut shares of Afya from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 29th. Bradesco Corretora upgraded shares of Afya to an “outperform” rating and set a $17.00 target price for the company in a report on Thursday, September 24th. Finally, Morgan Stanley raised Afya from an “underweight” rating to an “equal weight” rating and set a $12.60 target price on the stock in a research report on Thursday, November 5th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Afya currently has a consensus rating of “Hold” and an average target price of $15.18.
Check Out Our Latest Research Report on Afya
Afya Price Performance
AFYA stock opened at $10.51 on Friday. The business has a fifty day moving average of $13.08 and a two-hundred day moving average of $14.07. The company has a quick ratio of 2.20, a current ratio of 2.20 and a debt-to-equity ratio of 0.39. The stock has a market cap of $985.00 million, a price-to-earnings ratio of 6.06, a price-to-earnings-growth ratio of 1.71 and a beta of 0.43. Afya has a 52-week low of $9.66 and a 52-week high of $16.16.
Afya (NASDAQ:AFYA – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03. The business had revenue of $187.80 million for the quarter, compared to analyst estimates of $189.62 million. Afya had a return on equity of 17.58% and a net margin of 20.55%. As a group, research analysts anticipate that Afya will post 1.68 earnings per share for the current year.
Insiders Place Their Bets
In other Afya news, insider Santos Welder Ferreira sold 4,161 shares of Afya stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $13.30, for a total value of $55,341.30. Following the completion of the transaction, the insider directly owned 35,000 shares of the company’s stock, valued at $465,500. The trade was a 10.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new stake in shares of Afya during the 2nd quarter worth about $67,000. Engineers Gate Manager LP purchased a new stake in Afya during the second quarter worth approximately $325,000. Finally, R Squared Ltd lifted its stake in Afya by 37.0% during the third quarter. R Squared Ltd now owns 60,114 shares of the company’s stock worth $724,000 after purchasing an additional 16,250 shares during the last quarter. Hedge funds and other institutional investors own 88.02% of the company’s stock.
About Afya
Afya Limited is a Brazilian medical education and digital health company. Its education business offers undergraduate medical degree programs, medical residency preparation, postgraduate courses and continuing education for health professionals. The company also provides digital tools and services for medical students and practicing physicians, including clinical reference, practice-management and learning resources. These offerings support professionals at different stages of their medical careers.
See Also
- Five stocks we like better than Afya
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
